Halozyme 2022 Q4 & Full Year Earnings Results | HALO Investor Update

Halozyme reported 2022 total revenue of $660.1M with EBITDA of $314.5M and non-GAAP diluted EPS of $2.21. The company provided 2023 financial guidance projecting total revenue of $815M–$845M and EBITDA of $445M–$455M, driven by full-year Antares contribution and increased ENHANZE® API demand. Halozyme's ENHANZE® drug delivery technology platform continues to generate royalty revenue from partner collaborations including DARZALEX® and Phesgo® uptake.